Volume 14, Number 11—November 2008
Research
Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
Figure
![Kaplan-Meier plot showing the time to sputum smear conversion according to treatment received (linezolid-containing regimen, n = 74, vs. linezolid-sparing regimen, n = 110) in Germany (log-rank test 0.0924). The proportion of case-patients reaching conversion is shown along the vertical axis.](/eid/images/08-0729-F1.jpg)
Figure. Kaplan-Meier plot showing the time to sputum smear conversion according to treatment received (linezolid-containing regimen, n = 74, vs. linezolid-sparing regimen, n = 110) in Germany (log-rank test 0.0924). The proportion of case-patients reaching conversion is shown along the vertical axis.
1Additional German Tuberculosis Network European Trials group (TBNET) contributors: R. Eberhardt, Thorax-Clinic-Heidelberg, Heidelberg; A. Esselmann, Pulmonary Clinic, Hemer; H. Flick, Charité, Berlin; M. Hamm, Hospital Diekholzen, Diekholzen; P. Hammerl, Hospital Immenhausen, Immenhausen; H. Hang, Hospital Schillerhöhe, Schillerhöhe; P. Hannemann, Deakoness Hospital, Neustadt; D. Hillemann, Research Center Borstel, Borstel; B. Kretz, Asklepios Hospital, Gauting; C. Laumanns, Bethania Hospital, Solingen; G. Liebetrau, Lostau Hospital, Lostau; S. Ott, Helios Clinic Emil von Behring, Berlin; A. Paulick, Pulmonary Clinic-Coswig, Coswig; M.W. Pletz, Hannover Medical School, Hannover; M. Rau, Pulmonary Clinic, Wangen; G. Rohde, Bergmannsheil Hospital, Bochum; A. de Roux, Evangelische Lungenklinik, Berlin; C. Schaudt, Hospital St. Blasien, St. Blasien; K-D.Schneider, Pulmonary Clinic, Hannover-East, Hannover; S. Stenger, University Hospital, Ulm; D. Wagner, University Hospital, Freiburg; and T. Wolf, University Hospital, Frankfurt.